1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Multiple Sclerosis: KOL Insight 2016

Multiple Sclerosis: KOL Insight 2016

  • November 2016
  • ID: 4833573

Summary

Table of Contents

Description

Big changes ahead as Ocrevus nears approval. How will it affect your brand?

Oral therapies are replacing interferons as the mainstay Multiple Sclerosis (MS) treatment, but the big news is the pending approval of Roche/Biogen’s Ocrevus, a powerful monoclonal antibody for relapsing and progressive MS patients that promises to upend the treatment algorithm.

Get the details in KOL Insight: Multiple Sclerosis.
Based on interviews with 12 US and European KOLs, the report gives you their candid thoughts about 12 marketed therapies and 11 more in the pipeline.

You’ll learn what the future holds for interferons, how oral agents are faring, and how pipeline treatments—from sphingosine modulators, to monoclonal antibodies, pharmaceutical-grade biotin, and other novel mechanisms of action—are likely to compete with established therapies.

“Ocrevus has the potential to really change the landscape and, from a patient perspective, sounds pretty easy.” EU Key Opinion Leader
- Prof Shiv Saidha, MD, MBBCh. Associate Professor of Neurology, Johns Hopkins Medicine, Baltimore, Maryland, USA.
- Prof Bianca Weinstock-Guttman, MD. Professor of Neurology and Director of the Jacobs Multiple Sclerosis Center for Treatment and Research, University at Buffalo, New York, USA.
- Prof Mark Freedman, MD. Professor of Medicine in the field of Neurology, University of Ottawa and Director of the Multiple Sclerosis Research Unit, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada.
- Prof Gilles Defer, MD. Head of the Department of Neurology, University Hospital of Caen, France.
- Prof Per Soelberg Sørensen, MD. Professor of Neurology, University of Copenhagen and Director of the Danish Multiple Sclerosis Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Top Takeaways
- Once approved, Ocrevus will revolutionise MS treatment: Not just the relapsing remitting form but progressive forms as well, KOLs say. What are the most likely indications for Ocrevus, and will it see first-line usage?
- Interferons in decline: More neurologists are prescribing other agents instead, a trend KOLs expect to continue even as interferon use persists in specific indications. What’s behind the drop-off in interferon use, and in which patients will doctors continue to prescribe them?
- Next-generation sphingosine modulators may threaten Gilenya: What will these pipeline agents need to show to gain widespread adoption?
- Copaxone still going strong: Considered the safest MS therapy, Copaxone continues to appeal to risk-averse patients. Has the introduction of generic glatiramer acetate had an impact on Copaxone prescribing?
- Future unclear for Zinbryta: Launched into a crowded marked, Biogen/AbbVie’s Zinbryta may struggle to find a niche. What advantages and drawbacks do KOLs say will determine the drug’s short-term prospects? Which potential competitor looms longer-term?
- Tecfidera use has plateaued: Safety concerns have made neurologists more cautious about using Tecfidera. Do KOLs expect prescriptions to decline or stay the same? Which Tecfidera competitor is benefitting most from the uncertainty?
- KOLs excited about MD 1003: Intrigued by the potential of pharmaceutical-grade biotin, KOLs are calling for larger trials. What are their most pressing questions and concerns? Where do they see MD 1003 entering the treatment algorithm?
- Novel MoAs hold promise: Despite disappointing study results, KOLs are keeping a close eye on Biogen’s anti-LINGO-1 mAb, opicinumab. What has them interested, and what do they suggest as next steps for evaluating the drug?


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
2018 Global Tumor Marker Testing Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers

2018 Global Tumor Marker Testing Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers

  • $ 17500
  • Industry report
  • September 2018
  • by Venture Planning Group

Highlights- Identifies and evaluates major business opportunities emerging in the tumor marker market during the next five years.- Examines trends in the U.S., Europe and Japan- Reviews current and emerging ...

2018 US Hematology and Flow Cytometry Analyzers and Reagents: Supplier Sales and Shares, Sales Segment Forecasts--Hospitals, Commercial Laboratories, POC Locations--Competitive Landscape, Emerging Technologies, Instrumentation Review

2018 US Hematology and Flow Cytometry Analyzers and Reagents: Supplier Sales and Shares, Sales Segment Forecasts--Hospitals, Commercial Laboratories, POC Locations--Competitive Landscape, Emerging Technologies, Instrumentation Review

  • $ 7500
  • Industry report
  • July 2018
  • by Venture Planning Group

Complete report $11,500.  DataPack (test volumes, sales forecasts, supplier shares) $7,500.Summary This comprehensive report contains 306 pages, 59 tables, and is designed to help current suppliers and ...

2018 US Coagulation Testing Analyzers and Reagents: Supplier Sales and Shares, Sales Segment Forecasts--Hospitals, Commercial Laboratories, POC Locations--Competitive Landscape, Emerging Technologies, Instrumentation Review

2018 US Coagulation Testing Analyzers and Reagents: Supplier Sales and Shares, Sales Segment Forecasts--Hospitals, Commercial Laboratories, POC Locations--Competitive Landscape, Emerging Technologies, Instrumentation Review

  • $ 7500
  • Industry report
  • July 2018
  • by Venture Planning Group

Complete report $11,500.  DataPack (test volumes, sales forecasts, supplier shares) $7,500.SummaryThis comprehensive report contains 455 pages, 60 tables, and is designed to help current suppliers and ...


ref:plp2016

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on